Development of a live, attenuated, recombinant vaccine for Brucellosis

Files

7364745.pdf (3.47 MB)
Downloads: 174

TR Number

Date

2008-04-29

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

United States Patent and Trademark Office

Abstract

A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.

Description

Keywords

Citation